Table 2 Single factor analysis after matching analysis.

From: Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells

 

OS

RFS

Variables

Value

N

Events

HR(95%CI)

P

N

Events

HR(95%CI)

P

ATO

No

57

15

1

 

57

14

1

 

Yes

19

1

0.15(0.02, 1.1)

0.03

19

2

0.32(0.07, 1.41)

0.112

Age

 < 60

47

10

1

 

47

11

1

 

 ≥ 60

29

6

0.81(0.29, 2.23)

0.682

29

5

0.62(0.22, 1.8)

0.38

Gender

Male

14

1

1

 

14

2

1

 

Female

62

15

3.21(0.42, 24.32)

0.233

62

14

1.47(0.33, 6.49)

0.607

BMI

 < 24

40

9

1

 

40

8

1

 

 ≥ 24

36

7

0.81(0.3, 2.18)

0.68

36

8

1.05(0.39, 2.79)

0.929

Smoking

No

56

14

1

 

56

11

1

 

Yes

20

2

0.4(0.09, 1.76)

0.209

20

5

1.29(0.45, 3.72)

0.638

Alcohol

No

56

15

1

 

56

12

1

 

Yes

20

1

0.17(0.02, 1.26)

0.048

20

4

0.83(0.27, 2.58)

0.745

Diabetes

No

42

10

1

 

42

8

1

 

Yes

34

6

0.76(0.28, 2.09)

0.594

34

8

1.26(0.47, 3.37)

0.639

Hypertension

No

39

13

1

 

39

11

1

 

Yes

37

3

0.2(0.06, 0.69)

0.005

37

5

0.39(0.14, 1.13)

0.073

AFP

 < 400

52

12

1

 

52

9

1

 

 ≥ 400

24

4

0.67(0.21, 2.08)

0.482

24

7

1.71(0.63, 4.63)

0.286

BCLC stage

0 or A

62

10

1

 

62

12

1

 

B or C

14

6

4.27(1.46, 12.5)

0.004

14

4

2.38(0.73, 7.71)

0.136

Child pugh

A

71

13

1

 

71

15

1

 

B

5

3

7.48(2.04, 27.48)

 < 0.001

5

1

1.78(0.23, 13.75)

0.576

Cirrhosis

No

58

9

1

 

58

13

1

 

Yes

18

7

3.18(1.18, 8.58)

0.016

18

3

0.9(0.26, 3.19)

0.876

Clonorchissinensis

No

66

15

1

 

66

14

1

 

Yes

10

1

0.51(0.07, 3.9)

0.513

10

2

1.04(0.24, 4.58)

0.961

Venous tumor thrombus

No

66

12

1

 

66

13

1

 

Yes

10

4

3.73(1.14, 12.2)

0.019

10

3

2.72(0.74, 10.02)

0.118

Tumor number

1

70

13

1

 

70

15

1

 

 ≥ 1

6

3

3.66(1.01, 13.21)

0.034

6

1

0.98(0.13, 7.54)

0.987

Tumor size max

 < 5 cm

35

7

1

 

35

3

1

 

 ≥ 5 cm

41

9

1.42(0.52, 3.86)

0.489

41

13

4.84(1.37, 17.19)

0.007

Hepatitis

No

22

4

1

 

22

6

1

 

HBV

54

12

1.35(0.44, 4.19)

0.601

54

10

0.7(0.25, 1.92)

0.481

MVI

No

50

11

1

 

50

8

1

 

Yes

26

5

1.11(0.38, 3.2)

0.852

26

8

2.4(0.9, 6.44)

0.073

Duration of operation

 < 240

37

6

1

 

37

6

1

 

 ≥ 240

39

10

1.78(0.65, 4.92)

0.257

39

10

1.74(0.63, 4.79)

0.282

Bleeding

 < 400

43

6

1

 

43

9

1

 

 ≥ 400

33

10

2.31(0.84, 6.37)

0.095

33

7

1.05(0.39, 2.83)

0.917

Surgical approach

Open surgery

59

12

1

 

59

14

1

 

Laparoscope

17

4

1.13(0.37, 3.52)

0.828

17

2

0.5(0.11, 2.18)

0.343

Radical resection

Yes

51

9

1

 

51

7

1

 

No

25

7

1.52(0.56, 4.09)

0.407

25

9

2.62(0.98, 7.06)

0.047

  1. ATO, Atorvastatin. BMI, Body mass index. AFP, alpha-fetoprotein. BCLC, Barcelona clinic liver cancer stage. MVI, Microvascular Invasion. HBV, Hepatitis B Virus. HR, calaulated by Cox proportional hazards regression model. P, calaulated by log-rank test.